Publications
RXi Publications
- Ligtenberg et al. Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma. Molecular Therapy (2018), https://doi.org/10.1016/j.ymthe.2018.04.015
- Cauwenbergh, G. Believe in RNAi. The Medicine Maker; Web November 2017.
- Van Zuidam, J. Delving into RXi's RNAi Delivering Platform. Drug Discovery & Development. Web November 2017.
- BioVox. Immunotherapy: a cure for cancer? Belgium. Web 2017 May 18.
- Eliseev, E. Enhancing Immuno-Oncology with RNA Interference. DDNews; Web 2017 April 2017.
- Cauwenbergh, G. Age-Related Macular Degeneration: On the Rise as Baby Boomers Age. The Western PA Healthcare News; Web 2016 October 11.
- Graf, J. Dermal Scarring Challenges. The Dermatologist. August 2016; 24 (8).
- Cauwenbergh, G. RNAi-Based Therapeutics: A Novel Platform for Drug Development. Drug Discovery & Development; Web 2016 May 09.
- Byrne M, Tzekov R, Wang Y, Rodgers A, Cardia J, Ford G, et al. Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the Eye. Journal of Ocular Pharmacology and Therapeutics 2013.
- Lapierre J, Salomon W, Cardia J, Bulock K, Lam J, Stanney, W, et al. Potent and Systematic RNAi Mediated Silencing with Single Oligonucelotide Compounds. RNA 2011; 17:00–00.
- Salomon W, Bulock K, Lapierre J, Pavco P, Woolf T & Kamens J. Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC. Nucleic Acids Research 2010; 38 (11): 3771–3779.
RNAi and Disease Indication Publications
- Chiang K, Atanaskova Mesinkovska N, Amoretti A, Piliang MP, Kyei A, Bergfeld WF. Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Am Acad Dermatol. 2014 Sep;71(3):595-7. doi: 10.1016/j.jaad.2014.04.036.
- Cullen, K.A., Hall, M.J. & Golosinskiy, A. Ambulatory surgery in the United States, 2006. Natl Health Stat Report 2009; 1-25.
- Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol. 2014 Mar;109(4):308-13. doi: 10.1002/jso.23506. Epub 2013 Nov 19.
- Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
- Fire A, Xu S, Montgomery MK, Kostas SA, Driveri SE & Mello C. Potent and specific RNA interference by double-stranded RNA in Caenorhadbditis elegans. Nature 1998; 391 (6669):806-811.
- Gauglitz, G.G., Kortin, H.C., Pavicic, T., Ruzicka, T., & Jeschke, M.G. Hypertrophic scarring and keloids: pathomechanisms and current emerging treatment strategies. Mol Med 2011; 17(1-2): 113-125.
- Li-Tsang, C.W., Lau, J.C. & Chan, C.C. Prevalence of hypertrophic scar formation and its characteristics among the Chinese population. Burns 2005; 31, 610-616.
- Sisco M., Kryger Z.B., O’Shaughnessy K.D., Kim P.S., Schultz G.S., Ding X.Z., et al. Antisense inhibition of connective tissue growth factor (CTGF / CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound Repair and Regeneration 2008; 16, 661-673
- Upitis JA, Krol A. The use of diphenylcyclopropenone in the treatment of recalcitrant warts. J Cutan Med Surg. 2002 May-Jun;6(3):214-7. Epub 2002 Apr 15.
- Wang H, Ghosh A, Baigude H, Yang C, Qui L, Xia L, et al. Therapeutic gene silencing delivered by a chemically modified siRNA against mutant SOD1 slows ALS progression. JBC 2008; 283 (23):15845-15852.
- Weiser, T.G., Regenbogen, S.E., Thompson, K.D., Haynes, A.B., Lipsitz, S.R., Berry, W.R. & Gawande, A.A. An estimation of the global volume of surgery: a modeling strategy based on available data. Lancet 2008; 372(9633):139-44.
